Humacyte Accounts Payable vs Capital Stock Analysis
| HUMAW Stock | USD 1.71 0.24 16.33% |
Humacyte financial indicator trend analysis is much more than just examining Humacyte latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Humacyte is a good investment. Please check the relationship between Humacyte Accounts Payable and its Capital Stock accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Humacyte Stock please use our How to Invest in Humacyte guide.
Accounts Payable vs Capital Stock
Accounts Payable vs Capital Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Humacyte Accounts Payable account and Capital Stock. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Humacyte's Accounts Payable and Capital Stock is -0.43. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Capital Stock in the same time period over historical financial statements of Humacyte, assuming nothing else is changed. The correlation between historical values of Humacyte's Accounts Payable and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Humacyte are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Accounts Payable i.e., Humacyte's Accounts Payable and Capital Stock go up and down completely randomly.
Correlation Coefficient | -0.43 |
| Relationship Direction | Negative |
| Relationship Strength | Very Weak |
Accounts Payable
An accounting item on the balance sheet that represents Humacyte obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Humacyte are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Capital Stock
The total amount of a company's capital funded by shareholders through the issue and subscription of shares.Most indicators from Humacyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Humacyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Humacyte Stock please use our How to Invest in Humacyte guide.Enterprise Value is likely to climb to about 284.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 21.1 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 4.3M | 6.2M | 1.1M | 1.1M | Depreciation And Amortization | 8.3M | 8.3M | 7.7M | 8.7M |
Humacyte fundamental ratios Correlations
Click cells to compare fundamentals
Humacyte Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.